Novartis’ recently departed oncology R&D chief is headed back to Dana-Farber and a new job in cancer research
The revolving door at Novartis has spit out another top executive, only this one is headed back to a faculty post at Dana-Farber Cancer Institute and Harvard Medical School.
William Sellers had been in charge of oncology research at Novartis before he announced his “retirement” earlier this year. But his 11-year stint at the Novartis Institutes for BioMedical Research was not his final turn at bat in drug research. His new faculty post includes responsibilities as a senior adviser on experimental meds. And he’ll still be directly engaged on early-stage drug development at Dana-Farber, where he’ll help guide a spectrum of work that runs from target validation to early human studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
